ArticleSchizophrenia (Heidelberg, Germany)2023
Influencing factors of medication adherence in schizophrenic patients: a meta-analysis.
Article in Schizophrenia (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Digital Therapeutics for People with Schizophrenia Spectrum Disorders: A Systematic Literature Review of Their Effect on Symptoms and Functioning.Schizophrenia bulletin · 2026Pooled it
- Does Adjuvant Metformin Reduce Olanzapine-Induced Metabolic Adverse Effects in Patients Diagnosed With Schizophrenia.Neuropsychopharmacology reports · 2025Pooled it
- Non-adherence level of pharmacotherapy and its predictors among mental disorders in a resource-limited life trajectories: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Family-based interventions versus standard care for people with schizophrenia.The Cochrane database of systematic reviews · 2024Pooled it
- Feasibility and preliminary effectiveness of electronic medication monitoring system to improve antipsychotic adherence: a type 1 effectiveness-implementation hybrid pilot study.BMC psychiatry · 2026Trial
- Effectiveness of a peer-facilitated, recovery-focused self-illness management program for adults with first-episode psychosis: A randomized controlled trial.European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- Repurposing Antipsychotic Agents in Oncology: Mechanistic Rationale, Emerging Evidence, and Therapeutic Potential.Cancers · 2026Review
- Integrated Psychological-Behavioral Predictive Model Using Explainable Machine Learning.Healthcare (Basel, Switzerland) · 2026Article
- Treatment Adherence and Health Care Utilization After a First Episode of Psychosis.JAMA network open · 2026Article
- The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia.CNS drugs · 2026Review
- Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies.Journal of clinical medicine · 2026Review
- Novel positive allosteric modulators of alpha 5 subunit-containing GABASchizophrenia research · 2026Article
- Assessing treatment adherence in psychiatry: a comparison of clinical judgment and therapeutic drug monitoring in acute care.International clinical psychopharmacology · 2026Article
- Perception and willingness toward second-generation long-acting antipsychotics among patients with schizophrenia: a cross-sectional survey in Fujian, China.Frontiers in psychiatry · 2026Article
- Stakeholders' perceptions of recovery from psychosis in Blantyre, Malawi: Definitions, goals, and interventions.PLOS mental health · 2026Article
- Low willingness and patient-caregiver concordance regarding long-acting injectable antipsychotics in schizophrenia cases: a convergent mixed-methods study.Frontiers in psychiatry · 2026Article
- Validation and reliability of the Thai version of the glasgow antipsychotic side-effect scale (GASS) in patients with schizophrenia.Frontiers in pharmacology · 2026Article
- Dealing with Early-Onset Schizophrenia and the Role of Lurasidone: An Expert Opinion.Current neuropharmacology · 2026Review
- Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States.Patient preference and adherence · 2026Article
- Empowering clinicians and patients in antipsychotic dose reduction for schizophrenia: the role of online tools.Schizophrenia (Heidelberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication adherence of schizophrenic patients is a growing public health problem. We conducted a meta-analysis on the influencing factors of medication compliance in schizophrenic patients. We searched PubMed, Embase, Cochrane Library, and Web Of Science for relevant articles published up to December 22, 2022. Combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess influencing factors. Egger's test, funnel plot, the trim and fill method, and meta-regression analysis were used to assess publication bias. A total of 20 articles were included in the analysis. Twenty influencing factors were divided into seven categories: drug factors (OR = 1.96, 95% CI: 1.48-2.59), problem behavior (OR = 1.77, 95% CI: 1.43-2.19), income and quality of life (OR = 1.23, 95% CI: 1.08-1.39), personal characteristics (OR = 1.21, 95% CI: 1.14-1.30), disease factors (OR = 1.14, 95% CI: 1.98-1.21), support level (OR = 0.54, 95% CI: 0.42-0.70), and positive attitude and behavior (OR = 0.52, 95% CI: 0.45-0.62). This meta-analysis found that drug factors, disease factors, problem behavior, low income and quality of life, and factors related to personal characteristics appear to be risk factors for medication adherence in people with schizophrenia. And support level, positive attitude and behavior appear to be protective factors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.